Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03495882 · ClinicalTrials.gov registry record · Phase 1
Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical)
A Phase 1 study, sponsored by Agenus.
- Completed
- Registry status
- Phase 1
- Development phase
- 154
- Enrollment target
NCT03495882 is a Phase 1 study that has completed, run by Agenus. The registered enrollment target is 154 participants.
The verdict
NCT03495882, a Phase 1 study, has completed, sponsored by Agenus.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 154 participants
- Enrollment target
Study Summary
This is a Phase 1/2, open-label study of AGEN1884 in combination with AGEN2034 in subjects with locally advanced, recurrent and/or metastatic solid tumors including cervical cancer. AGEN2034 is a novel, fully human monoclonal immunoglobulin G4 (IgG4) antibody, designed to block program cell death-1 (PD-1). AGEN1884 is a novel, fully human monoclonal immunoglobulin G1 (IgG1) antibody, designed to block cytotoxic T-lymphocyte antigen-4 (CTLA-4).
Interventions
- DRUG AGEN1884 + AGEN2034
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2017-12-18 |
| Est. Completion | 2022-07-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03495882
The ClinicalTrials.gov registry entry for NCT03495882 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 154 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Agenus, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AGEN1884 + AGEN2034 is the first listed.
NCT03495882 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03495882 about?
NCT03495882 is a clinical study titled "Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical)". This is a Phase 1/2, open-label study of AGEN1884 in combination with AGEN2034 in subjects with locally advanced, recurrent and/or metastatic solid tumors including cervical cancer. AGEN2034 is a novel, fully human monoclonal immunoglobulin G4 (IgG4) antibody, designed to block program cell death-1 ...
What is the current status of trial NCT03495882?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 154 participants. The study started on 2017-12-18. Estimated completion is 2022-07-15.
What interventions are being tested in trial NCT03495882?
The interventions under investigation include: AGEN1884 + AGEN2034 (DRUG).
Who is sponsoring clinical trial NCT03495882?
This trial is sponsored by Agenus, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.